6th October 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Indian cough syrups allegedly causes death of 66 children in Gambia, WHO warns about 4 formulations

World Health Organisation (WHO) raised an alarm over the use of four cough syrups made by an Indian company after the alleged death of 66 children in the Gambia. It is now conducting investigation with the Haryana-based company and the regulatory authorities.

Myovant Sciences declines $2.5 billion takeover bid by Sumitovant Biopharma

Sumitovant Biopharma has 52% of outstanding shares in Myovant and they posposed to acquire the remaining shares for $22.75 per share in cash. After announcing the rejection of the offer, Myovant reasoned that the proposed bid “significantly undervalues” them.

US Supreme court turns down Biogen's plea to reinstate the patent of multiple sclerosis drug

The US Apex Court refused to hear Biogen Inc’s request to win a reinstatement of the patent for their megahit drug Tecfidera indicated for multiple sclerosis, giving Viatris Inc subsidiary (VTRS.O) Mylan Pharmaceuticals Inc. the right to move forward with the generic version of the drug.

Entod Pharma reaches final stages of drug development for eye drops to treat Presbiopia

The Mumbai-based Pharmaceutical Company claims that they are in the final stages of development of an eye formulation that can change the lives of millions of elderly people suffering from Presbiopia. The clinical trials have shown positive results worldwide including the US.

Unichem recalls 18960 bottles of hypertension drug over product mix-up

Unichem Pharmaceuticals US Inc has decided to recall 18960 bottles of its hypertension drug Clonidine Hydrochloride from the US Market. As per the regulatory authority, 0.2 mg strength Tablets, USP were found in a 100-count bottle of 0.3 mg strength tablets.

Novo Nordisk joins hands with Ventus therapeutics for NLRP3 Inhibitor Program

The Biopharmaceutical Company Ventus Therapeutics, Inc. has entered into an exclusive worldwide license agreement with Novo Nordisk A/S to work on the the development and marketing of peripherally-restricted NLRP3 inhibitors for which it holds the rights.

US FDA grants ODD to Poxel’s PXL770

The US regulatory body has granted ODD (Orphan Drug Designation) to the Clinical Stage Biopharmaceutical Company, Poxel SA for its novel first-in-class drug PXL770 which will be used to treat patients suffering from autosomal-dominant polycystic kidney disease (ADPKD).

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?